Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 3 years. On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study. The study showed that an investigational type II JAK2 inhibitor delivered an "encouraging" safety profile, demonstrating clinical activity in patients living with myelofibrosis who have failed a type I JAK2 inhibitor.
The therapy is aimed at selectively binding the type II conformation of the JAK2 kinase, thus providing improved efficacy over current solutions. It will also offer a new option for patients who develop resistance to type I JAK2 inhibitors. This addition follows the completion of the acquisition.
Copyright: kadmy / 123RF Stock Photo
Earlier on June 9, Jefferies lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and reiterated a Buy rating. This comes after the company reported full data from retatrutide's TRIUMPH-1 obesity study and TRANSCEND-T2D-1 study. Despite some safety concerns, which the firm believes are manageable, the retatrutide's overall profile "will be difficult to beat," the firm said. Indeed, LLY is among the stocks with the best earnings growth for the next 3 years.
Eli Lilly and Company (NYSE:LLY) is an Indiana-based company specializing in human pharmaceutical products. Founded in 1876, the company offers products for cardiometabolic health, oncology, immunology, and migraine prevention.
The therapy is aimed at selectively binding the type II conformation of the JAK2 kinase, thus providing improved efficacy over current solutions. It will also offer a new option for patients who develop resistance to type I JAK2 inhibitors. This addition follows the completion of the acquisition.
Copyright: kadmy / 123RF Stock Photo
Earlier on June 9, Jefferies lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and reiterated a Buy rating. This comes after the company reported full data from retatrutide's TRIUMPH-1 obesity study and TRANSCEND-T2D-1 study. Despite some safety concerns, which the firm believes are manageable, the retatrutide's overall profile "will be difficult to beat," the firm said. Indeed, LLY is among the stocks with the best earnings growth for the next 3 years.
Eli Lilly and Company (NYSE:LLY) is an Indiana-based company specializing in human pharmaceutical products. Founded in 1876, the company offers products for cardiometabolic health, oncology, immunology, and migraine prevention.
4 months ago
